PTC’s Sephience Launch Lifts Sales as Milestone Payments and Acquisitions Shape Cash Flow

PTC Therapeutics’ newest medicine is growing quickly enough to change the company’s revenue mix. Sephience generated $181.9 million in the third quarter, up 20% from the previous three months, as the number of patients receiving the treatment passed 2,000 worldwide.

The launch has allowed PTC to raise its full-year product revenue outlook for a second consecutive quarter. It is also generating payments to the former owners of the medicine, while PTC commits capital to another rare-disease program. In September, the company completed its $111 million purchase of ST-920, an investigational gene therapy for Fabry disease.

PTC’s third-quarter results show a business with growing product sales and substantial financial resources, alongside a distinction between reported revenue and cash available to shareholders. The company continues to recognize royalties from the spinal muscular atrophy drug Evrysdi even though it has sold its rights to those payments.

All dollar amounts are U.S. dollars.

A growing treatment base

Sephience is an oral treatment for phenylketonuria, or PKU, an inherited condition in which the body cannot properly process the amino acid phenylalanine. Excess phenylalanine can damage the nervous system, making control of blood levels an important part of treatment.

The U.S. Food and Drug Administration approved Sephience in 2025 for patients as young as one month with PKU that responds to sepiapterin, its active ingredient. The medicine is used alongside a phenylalanine-restricted diet. Its U.S. label does not cover every patient with PKU: patients must show a reduction in blood phenylalanine to continue treatment.

The pivotal study included an initial period to identify responsive patients. In its randomized portion, 98 responsive patients aged two years and older received Sephience or placebo. Over the six-week treatment period, the Sephience group had a larger reduction in blood phenylalanine. The trial supports use in the responsive population; it does not establish that all patients with PKU will respond.

PTC reported more than 2,000 active patients worldwide at September 30, compared with 1,647 at June 30. Third-quarter Sephience revenue comprised approximately $145 million in the United States and $37 million internationally. Management said growth included patients switching from existing treatments as well as patients who had not been receiving drug therapy.

The U.S. remains the largest contributor, while access and reimbursement in additional countries could support international growth. Patient eligibility, prescribing decisions and sustained access will influence how much of the broader PKU population PTC can reach.

Product growth is changing the revenue mix

Sephience contributed roughly two-thirds of PTC’s third-quarter product revenue. The increase helped offset pressure on older products: the company attributed lower nine-month Emflaza sales to generic competition and lower Translarna sales to the European Commission’s adoption of a negative regulatory opinion.

The company’s results show both the benefit of higher sales and the cost of adding to its pipeline. Total revenue rose by $146.8 million year over year. Operating income increased to $25.1 million even after PTC expensed the $111 million upfront cost of ST-920 as acquired in-process research and development.

Below operating income, net interest expense was $45.9 million, and PTC recorded a $19.3 million loss associated with extinguishing debt. Together with other expenses and tax, those items contributed to a $51.7 million net loss. The prior-year quarter included a $39.0 million tax benefit, which also affects the comparison.

PTC does not disclose a separate Sephience operating profit. Its product revenue growth is clear, but the consolidated accounts combine the costs of multiple medicines, research programs and corporate activities.

Higher guidance implies a steadier fourth quarter

PTC raised its 2026 product revenue guidance to $960 million–$990 million, from $850 million–$950 million previously. It also increased its total revenue outlook to $1.29 billion–$1.32 billion, from $1.18 billion–$1.28 billion.

Through September, product revenue was $740.3 million. The new annual range therefore implies approximately $219.7 million–$249.7 million in the fourth quarter, below the $275.9 million recorded in the third. The range leaves room for a lower quarter and does not, by itself, establish why management expects that outcome.

Management kept its annual guidance for research, development, selling, general and administrative expenses at $775 million–$815 million under GAAP. Its $680 million–$720 million non-GAAP range excludes an estimated $95 million of stock-based compensation. These figures cover the specified operating expense categories, not every cost in the income statement.

The widening Sephience contribution gives PTC more product revenue against which to fund its commercial infrastructure and research. At the same time, the launch must compensate for declines elsewhere in the portfolio.

Sales milestones and royalties affect retained cash

Sephience’s growth has already triggered payments under PTC’s acquisition agreement with Censa Pharmaceuticals, the medicine’s former owner. The quarterly filing says four consecutive quarters of global sales exceeded $250 million in the second quarter, triggering a $30 million payment. The corresponding $500 million threshold was crossed in the third quarter, triggering another $50 million. Both amounts were accrued at September 30.

PTC previously paid participating former Censa securityholders to cancel certain rights to sales-based payments. Other obligations, including specified sales milestones, remain. The accrued milestones are acquisition-related commitments associated with Sephience’s success and will require cash settlement.

A separate arrangement affects the company’s reported Evrysdi royalties. PTC sold Royalty Pharma its rights to receive those sales-based payments in exchange for funding totaling $2.1 billion. Because PTC accounts for the transaction as a financing, it continues to record royalty revenue and recognizes associated interest expense, even though Royalty Pharma owns the royalty rights.

That accounting treatment is significant when reading the income statement. The $81.7 million of third-quarter royalty revenue contributes to reported revenue, but investors should not treat it as an equivalent new cash stream retained by PTC. Three potential additional $20 million payments from Royalty Pharma depend on specified royalty thresholds in 2027, 2028 and 2029; they are contingent rather than cash already received.

For the first nine months of 2026, operating activities provided $44.8 million of cash. That included a $50 million Novartis development milestone, which the company identified as a principal contributor to operating cash flow. PTC’s positive figure therefore includes a milestone receipt alongside the cash effects of its commercial and research activities.

ST-920 adds a later-stage opportunity

PTC’s purchase of ST-920 adds a potential treatment for Fabry disease, an inherited disorder in which patients lack sufficient activity of an enzyme needed to break down certain fatty substances. The investigational therapy is designed to enable production of that enzyme after a one-time administration.

PTC completed the acquisition from Sangamo Therapeutics in September. In addition to the $111 million upfront payment, the agreement includes up to $100 million in contingent regulatory milestones. PTC expects to complete its U.S. biologics license application submission in the fourth quarter of 2026.

A submission would begin the regulatory review process; ST-920 is not yet an approved product. If approved, it could give PTC another medicine to sell through its rare-disease infrastructure. Its eventual contribution would depend on the regulatory outcome, clinical evidence, reimbursement and adoption.

PTC ended September with $2.13 billion in cash, cash equivalents and marketable securities. It also reported $536.3 million in debt and a $2.31 billion accounting liability associated with the sale of future royalties. The latter reflects the royalty-financing arrangement and should be considered alongside, rather than added mechanically to, a forecast of cash available from those same sold royalties.

For PTC, the near-term financial opportunity is continued growth in Sephience patients and sales without a proportionate increase in commercial spending. The next results will show whether that growth continues while the company pays the accrued milestones and advances ST-920 toward regulatory review.